Sean Bohen Sells 52,328 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) CEO Sean Bohen sold 52,328 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total value of $490,313.36. Following the completion of the sale, the chief executive officer now directly owns 298,836 shares of the company’s stock, valued at $2,800,093.32. This represents a 14.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Olema Pharmaceuticals Trading Up 0.4 %

Olema Pharmaceuticals stock opened at $6.75 on Friday. The firm has a 50 day simple moving average of $10.70 and a 200 day simple moving average of $11.86. Olema Pharmaceuticals, Inc. has a 1-year low of $6.24 and a 1-year high of $16.77. The firm has a market capitalization of $386.76 million, a price-to-earnings ratio of -3.08 and a beta of 1.92.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $27.00.

Hedge Funds Weigh In On Olema Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Victory Capital Management Inc. lifted its holdings in Olema Pharmaceuticals by 9.9% during the 3rd quarter. Victory Capital Management Inc. now owns 851,512 shares of the company’s stock worth $10,167,000 after purchasing an additional 76,720 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Olema Pharmaceuticals during the second quarter valued at about $945,000. Point72 Asset Management L.P. purchased a new stake in shares of Olema Pharmaceuticals in the second quarter worth about $34,753,000. Dana Investment Advisors Inc. bought a new position in shares of Olema Pharmaceuticals in the second quarter valued at approximately $808,000. Finally, Great Point Partners LLC grew its stake in Olema Pharmaceuticals by 25.5% during the third quarter. Great Point Partners LLC now owns 1,000,000 shares of the company’s stock valued at $11,940,000 after acquiring an additional 203,120 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.